Botox maker Allergan adds 'double-chin' drug with $2.1B deal

Botox maker Allergan Plc. is buying Kythera Biopharmaceuticals for about $2.1 billion, adding a drug that destroys fat cells and eliminates the cosmetic condition referred to as "double chin".

The Dublin drugmaker will pay $75 per share in a cash-and-stock deal for Kythera, based in Westlake Village, California. The deal marks a 25.5 percent premium over Kythera's closing stock price Tuesday.

Kythera Biopharmaceuticals Inc. is preparing to launch its double chin treatment Kybella in the U.S., and the company is seeking approval in foreign markets as well. It treats fat located below the chin by destroying fat cells.

The treatments take about 20 minutes and patients experience visible results in two to four treatments, according to Kythera. The company has said that it expects annual revenue from the drug to top $500 million.

Kybella would fit comfortably in Allergan's line of cosmetic injections. Botox is used cosmetically to prevent wrinkles, as is Juvederm. Latisse promotes eyelash growth.

Kythera's pipeline of experimental products includes setipiprant, aimed at preventing male pattern baldness.

Allergan was bought by Actavis for about $70.5 billion earlier this year. After completing the buyout, it opted to name the new combined company Allergan.

Kythera shares rose $13.42, or 22 percent, to $74.14 in morning trading Wednesday. Its shares have doubled over the past year.

Explore further

FDA approves injection for melting away double-chin fat

© 2015 The Associated Press. All rights reserved.

Citation: Botox maker Allergan adds 'double-chin' drug with $2.1B deal (2015, June 17) retrieved 28 May 2022 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Feedback to editors